# MERMAID-2 (NCT04642469)

> Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04642469
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AstraZeneca
- Conditions: Carcinoma, Non- Small Cell Lung
- Interventions: Durvalumab; Placebo
- Enrollment: 30
- Primary outcome: Disease-free Survival (DFS)

## Indexed commentary on MERMAID-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=mermaid-2-nct04642469